Back to discover

Protein / target

Tumor necrosis factor ligand superfamily member 10

Encoded byTNFSF10P50591Homo sapiensSwiss-Prot
UniProt: P50591Ensembl: ENSG00000121858HGNC: HGNC:11925NCBI Gene: 8743
Small-molecule tractable
Druggability
Med-Quality Pocket
1
Research papers

Protein at a glance

Biological role

Tumor necrosis factor receptor binding

Strongest disease association

Gout

Via encoding gene TNFSF10 · Genetic evidence · score 0.72

Research activity

Emerging research

1 papers · latest 2018

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG.

View complete UniProt function annotation

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis

Subcellular location

Cell membraneSecreted
Domains and Gene Ontology detail (21)

Domains & features

THD

Gene Ontology

  • Cextracellular exosome
  • Cextracellular region
  • Cextracellular space
  • Cplasma membrane
  • Fcytokine activity
  • Fidentical protein binding
  • Fsignaling receptor binding
  • FTRAIL binding
  • Ftumor necrosis factor receptor binding
  • Fzinc ion binding
  • Papoptotic process
  • Pcell surface receptor signaling pathway

281 aa · 33 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GOApoptosis & cell deathGO
View supporting evidence

Immune signalling

  • ·Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10…
  • ·cytokine activity
  • ·immune response

Apoptosis & cell death

  • ·apoptotic process
  • ·positive regulation of apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TNFSF10

Gene-level evidence surfaced through the gene TNFSF10 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Gout
0.73Moderately supported

Genetic evidence dominant · Open Targets 0.44

Triple Negative Breast Neoplasms
0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Cholelithiasis
0.60Moderately supported

Genetic evidence dominant · Open Targets 0.36

Prostate carcinoma
0.59Moderately supported

Genetic evidence dominant · Open Targets 0.35

Pericarditis
0.39Limited support

Genetic evidence dominant · Open Targets 0.24

View evidence synthesis (5)
GoutModerately supported
0.73
agreement 0.59–0.87
Genetic99%Literature2%

Open Targets aggregate 0.44 · 2 independent evidence families

Triple Negative Breast NeoplasmsModerately supported
0.63
agreement 0.49–0.77
Genetic96%Literature4%

Open Targets aggregate 0.38 · 2 independent evidence families

CholelithiasisModerately supported
0.60
agreement 0.48–0.72
Genetic100%

Open Targets aggregate 0.36 · 1 independent evidence family

Prostate carcinomaModerately supported
0.59
agreement 0.45–0.73
Genetic79%Literature21%

Open Targets aggregate 0.35 · 2 independent evidence families

PericarditisLimited support
0.39
agreement 0.27–0.51
Genetic100%

Open Targets aggregate 0.24 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Gout0.44
Triple Negative Breast Neoplasms0.38
Cholelithiasis0.36
Prostate carcinoma0.35
Pericarditis0.24
Carcinoma, Renal Cell0.20
Glioblastoma0.12

Tractability

Small molecules — Emerging

Feasibility evidence (med-quality pocket and druggable family) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Med-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2018

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.211 cites

DeSelm C · Molecular therapy : the journal of the American Society of Gene Therapy · 2018

Recent

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

DeSelm C · Molecular therapy : the journal of the American Society of Gene Therapy · 2018

Europe PMC papers linked directly to this protein.